Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
Tags:
clinical trials, Takeda, Zinfandel Pharmaceuticals, pioglitazone, Alzheimer's disease, Boehringer Ingelheim, BI 409306, Merck, verubecestat, Celgene, MS, ozanimod, Incyte, ID01, melanoma, vTv Therapeutics, azeliragon, Roche, Tecentriq, Exelixis, colorectal cancer, JNJ, atabacestat, Sareptat Therapeutics, DMD, Exondys 51, Alkermes, ALKS-5461, clinical depression
Innovent, Incyte sign collaboration deal for three clinical-stage product candidates
Pharmaceutical Business Review
Mon, 12/17/18 - 09:02 am
Tags:
Incyte, Innovent Biologics, pemigatinib, itacitinib, parsaclisib
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
Tags:
M&A, Biomarin, Vertex Pharmaceuticals, Incyte, Alnylam, Alexion
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
Thu, 10/25/18 - 09:52 am
Tags:
FDA, Incyte, Novartis, Jakavi, Jakafi, graft vs host disease
Thu, 10/25/18 - 09:33 am
Tags:
Incyte, graft vs host disease, Novartis, Jakafi
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Fri, 09/21/18 - 09:55 am
Tags:
Agenus, Incyte, Merck, Xoma
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Thu, 06/21/18 - 11:00 pm
Tags:
Incyte, Jakafi, graft vs host disease
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Fri, 06/1/18 - 10:36 pm
Tags:
Eli Lilly, Incyte, FDA, rheumatoid arthritis, olumiant, baricitinib
3 Biotechs With Huge FDA Decisions in June
Motley Fool
Thu, 05/31/18 - 10:00 pm
Tags:
biotech, Array Biopharma, encorafenib, binimetinib, GW Pharma, Epidiolex, Incyte, olumiant
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
Thu, 05/31/18 - 08:17 pm
Tags:
ASCO, oncology, IDO inhibitors, Incyte
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
Tags:
ASCO 2018, European Society of Cardiology, TherapeuticsMD, Abiomed, Incyte, Bluebird Bio, Celgene, Syndax, Loxo Oncology, Exelixis, Karyopharm, Endocyte, Celldex Therapeutics, Jounce Therapeutics, Bristol-Myers Squibb, Nektar
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination
Fierce Biotech
Wed, 05/2/18 - 09:55 am
Tags:
Incyte, epacadostat, Keytruda, IDO inhibitors
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Mon, 04/23/18 - 11:15 pm
Tags:
Eli Lilly, FDA, advisory panels, rheumatoid arthritis, baricitinib, Incyte
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Sun, 04/22/18 - 12:12 pm
Tags:
Eli Lilly, earnings, FDA, Incyte, olumiant, rheumatoid arthritis
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Fri, 04/20/18 - 12:44 pm
Tags:
Incyte, TG Therapeutics, Cara Therapeutics, CR845, opioids, ublituximab, leukemia, olumiant, rheumatoid arthritis
[video]Why One Drug Flop Tanked Incyte's Stock
Motley Fool
Thu, 04/12/18 - 10:58 pm
Tags:
Incyte, epacadostat
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Motley Fool
Fri, 04/6/18 - 07:43 pm
Tags:
Incyte, Merck, epacadostat, IDO inhibitors, Roche, NewLink Genetics
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
Motley Fool
Fri, 04/6/18 - 07:41 pm
Tags:
Nektar Therapeutics, Incyte, Merck, NKTR-214, Bristol-Myers Squibb
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Fri, 04/6/18 - 09:51 am
Tags:
Incyte, Merck, melanoma, epacadostat, Keytruda, clinical trials, metastatic melanoma
3 Biotechs That Could Get Big Boosts in April
Motley Fool
Wed, 03/28/18 - 10:02 am
Tags:
biotech, GW Pharma, Epidiolex, Incyte, olumiant, baricitinib, Neurocrine Biosciences, Elagolix

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.